iECURE grabs $50m Series A
iECURE, a mutation-agnostic in vivo gene editing company, has secured $50 million in Series A financing.
iECURE, a mutation-agnostic in vivo gene editing company, has secured $50 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination